Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290904 | PMC |
| http://dx.doi.org/10.1001/jamaophthalmol.2025.2332 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Uveitis.
JAMA Ophthalmol
August 2025
Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Importance: Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly used for glycemic control in diabetes, may possess anti-inflammatory properties. Understanding their potential protective role against uveitis could provide insights into novel therapeutic strategies.
Objective: To evaluate whether being prescribed a GLP-1RA is associated with a reduced risk of developing uveitis.
GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity.
JAMA Oncol
August 2025
Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis.
Article Synopsis
- GLP-1 receptor agonists (GLP-1RAs) are commonly used for type 2 diabetes management and weight loss, but their long-term effects on cancer risk are unclear, highlighting the need for patient safety understanding.
- This study compared cancer incidence among adults with obesity prescribed GLP-1RAs versus nonusers using electronic health data from 2014 to 2024, including 86,632 participants.
- Results indicated that GLP-1RA users had a lower overall cancer risk (13.6 vs 16.4 per 1000 person-years) and were particularly at reduced risk for endometrial and ovarian cancers.
Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations.
Diabetol Metab Syndr
August 2025
Department of Pharmacy, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are extensively prescribed to treat obesity and diabetes. However, previous studies have debated whether GLP-1RA use induces diabetic retinopathy (DR) in diabetic populations, and the relationship between the two is unclear.
Methods: Cis-expressed quantitative trait locus data (Cis-eQTL) in blood tissue were used to extract single nucleotide polymorphisms (SNPs) as a genetic proxy tool.
GLP-1RA Exposure and Nonarteritic Anterior Ischemic Optic Neuropathy Prevalence by Diabetes Status.
JAMA Ophthalmol
July 2025
Department of Epidemiology, School of Public Health, University of Alabama, Birmingham.
GLP-1RA-Associated Diabetic Lumbosacral Radiculoplexus and Common Fibular Neuropathies: A Case-Control Evaluation.
Neurology
August 2025
Department of Neurology, Mayo Clinic, Rochester, MN.
Background And Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used to treat obesity and diabetes. Semaglutide, a GLP-1RA, is linked to nonarteritic ischemic optic neuropathy (NAION), macular edema, and retinopathy. Because diabetic lumbosacral radiculoplexus neuropathy (DLRPN) and common fibular neuropathy (CFN) are associated with weight loss, we examined whether GLP-1RA usage is linked to these neuropathies.
View Article and Find Full Text PDF